Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 116,100 shares, a growth of 1,175.8% from the November 30th total of 9,100 shares. Based on an average trading volume of 1,150,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 8.5% of the company’s shares are sold short.
Arcadia Biosciences Stock Down 0.7 %
Shares of RKDA traded down $0.04 during trading hours on Friday, reaching $6.11. The company’s stock had a trading volume of 69,202 shares, compared to its average volume of 315,605. The company has a 50 day moving average of $4.40 and a two-hundred day moving average of $3.43. The firm has a market cap of $8.34 million, a price-to-earnings ratio of -1.43 and a beta of 1.18. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $10.31.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Arcadia Biosciences in a research report on Wednesday. They issued a “sell” rating for the company.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- The 3 Best Blue-Chip Stocks to Buy Now
- How AI Implementation Could Help MongoDB Roar Back in 2025
- How to Calculate Options Profits
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.